重组带状疱疹疫苗与痴呆风险
这项回顾性队列研究利用2017年1月1日至2022年12月31日的Optum Labs数据仓库去标识化理赔数据,纳入4,502,678名免疫功能正常者,评估重组带状疱疹疫苗与痴呆风险的关联。调整后,完整接种两剂与痴呆风险降低显著相关(HR 0.68;95%CI 0.67-0.70;P<.001),接种一剂亦相关(HR 0.89;95%CI 0.87-0.92;P<.001)。
要点
- 完整接种两剂重组带状疱疹疫苗与痴呆风险降低显著相关(HR 0.68;95%CI 0.67-0.70;P<.001)。
- 接种一剂亦与痴呆风险降低显著相关(HR 0.89;95%CI 0.87-0.92;P<.001)。
- 首次接种前有带状疱疹诊断与痴呆风险升高相关(HR 1.47;95%CI 1.42-1.52;P<.001)。
核心结论
- 研究结果提示重组带状疱疹疫苗与痴呆风险降低相关,并凸显疫苗接种在预防带状疱疹之外的额外获益。
研究设计与样本
- 回顾性队列研究,使用Optum Labs数据仓库2017年1月1日至2022年12月31日的去标识化理赔数据。
- 纳入连续入组≥365天的免疫功能正常患者,风险期自符合重组带状疱疹疫苗接种年龄资格起算。
- 采用Cox回归,调整固定时变及每6个月更新的时变指标,估计痴呆的风险比。
主要发现
- 共纳入4,502,678人(中位[IQR]年龄62[54-71]岁;51%女性),其中部分接种206,297人(4.6%),完整接种460,413人(10.2%)。
- 痴呆发病率:完整接种组99.1例/万人年,部分接种组108.2例/万人年,未接种组135.0例/万人年。
- 调整后,两剂接种与痴呆风险降低显著相关(HR 0.68;95%CI 0.67-0.70;P<.001),一剂接种亦相关(HR 0.89;95%CI 0.87-0.92;P<.001)。
- 首次接种前有带状疱疹诊断与痴呆风险升高相关(HR 1.47;95%CI 1.42-1.52;P<.001)。
- 用于治疗带状疱疹感染的抗病毒药物对痴呆具有保护作用(HR 0.42;95%CI 0.40-0.44;P<.001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Herpes zoster is a potential risk factor for dementia. The effectiveness of the recombinant zoster vaccine for preventing dementia is uncertain. METHODS: This retrospective cohort study used de-identified claims data from the Optum Labs Data Warehouse database from January 1, 2017, to December 31, 2022, to determine whether the recombinant zoster vaccine is associated with a reduced risk of dementia. Immunocompetent patients with ≥365 days of continuous enrollment were included, with the risk period starting upon age-eligibility for the recombinant zoster vaccination. Cox regression adjusted for time-fixed and time-updated measures every six months was implemented to estimate hazard ratios for dementia. Herpes zoster diagnosis and antiviral therapy were also assessed. RESULTS: There were 4,502,678 individuals (median [IQR] age, 62 [54-71] years; 51 % female) included in this study: 206,297 (4.6 %) were partially vaccinated, and 460,413 (10.2 %) were fully vaccinated. The incidence rate of dementia was 99.1 cases per 10,000 person-years in the fully vaccinated group, 108.2 cases per 10,000 person-years in the partially vaccinated group, and 135.0 cases per 10,000 person-years in the unvaccinated group. After adjustment, vaccination was significantly associated with a decreased risk of dementia for two doses (hazard ratio (HR): 0.68; 95 % CI: 0.67-0.70; P < .001) and for one dose (HR 0.89; 95 % CI: 0.87-0.92; P < .001). Having a herpes zoster diagnosis before the first vaccination dose was associated with an increased hazard of dementia (HR 1.47; 95 % CI: 1.42-1.52; P < .001) compared to those with no diagnosis. Antivirals used to treat zoster infection were protective against dementia (HR 0.42; 95 % CI: 0.40-0.44; P < .001). CONCLUSIONS: These findings suggest that the recombinant zoster vaccine is associated with a decreased risk of dementia and highlight an additional benefit of vaccination beyond preventing herpes zoster.
引用
- Tang E, Ray I, Arnold BF, et al. Recombinant zoster vaccine and the risk of dementia. Vaccine. 2024. PMID: 39733478. doi:10.1016/j.vaccine.2024.126673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。